BioCryst PharmaceuticalsBCRX +0.05%66 3-Year ROIIC % is 289.37 as of Dec. 2025, which is 125% above its 10-year median of 128.35. GuruFocus rates BCRX with a GF Score™ of 66/100 and a GF Value™ of $12.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 944 Drug Manufacturers companies, BioCryst Pharmaceuticals ranks better than 95.44% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
BioCryst Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 289.37%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for BioCryst Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
BCRX's 3-Year ROIIC % is ranked better than 95.44% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs BCRX: 289.37
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
BioCryst Pharmaceuticals 3-Year ROIIC % Related Terms
BioCryst Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCRX vs SUPN, PBH, AMLX: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
BioCryst Pharmaceuticals (BCRX) has a 3-Year ROIIC % of 289.37 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BioCryst Pharmaceuticals and its competitors. This is 125% above median its historical median of 128.35. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #43 out of 944 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is BioCryst Pharmaceuticals' 3-Year ROIIC % too high?
BioCryst Pharmaceuticals' current 3-Year ROIIC % of 289.37 is 125% above median its 10-year median of 128.35. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. BioCryst Pharmaceuticals' value of 289.37 is 7860.7% above this industry median. Based on the distribution chart, BioCryst Pharmaceuticals ranks #43 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' 3-Year ROIIC % compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #43 out of 944 companies for 3-Year ROIIC %. This places BioCryst Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. BioCryst Pharmaceuticals' value of 289.37 is 7860.7% above this benchmark. While the company's 10-year median is 128.35 vs. the industry median of 3.64, BioCryst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCryst Pharmaceuticals's current 3-Year ROIIC % of 289.37 is 7860.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current 3-Year ROIIC % is 289.37, which is 125% above median its own 10-year median of 128.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.57, compared to a current price of $11.02 — trading 12.4% below its estimated fair value. The current 3-Year ROIIC % is 289.37, which is 125% above median its 10-year median of 128.35 and 7860.7% above the Drug Manufacturers industry median of 3.64. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current 3-Year ROIIC % is 289.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.02 is trading 12.4% below its estimated GF Value™ of $12.57.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
3-Year ROIIC %: 289.37 (125% above median its 10-year median of 128.35)
GF Value™: $12.57 vs. price of $11.02 (12.4% below fair value)
Industry Position: 7860.7% above the Drug Manufacturers median (#43 of 944)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
66GF Score
Get the complete analysis for BCRX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
